What are the main indications for tocilizumab?

Tocilizumab is a targeted immunomodulatory drug mainly used to treat a variety of diseases caused by immune system abnormalities. Its mechanism of action is to reduce excessive immune responses and inflammatory responses by inhibiting the activity of IL-6 receptors, thereby alleviating diseases caused by immune system disorders. Tocilizumab has a wide range of indications, mainly including the following:

1. Rheumatoid arthritis (RA): Tocilizumab is most widely used in the treatment of rheumatoid arthritis, especially for patients who are ineffective or intolerant to traditional treatments (such as methotrexate). By inhibiting IL-6 receptors, it reduces joint inflammation and relieves joint swelling, pain and stiffness, thereby significantly improving patients' function and quality of life. The control effect of tocilizumab on rheumatoid arthritis has been verified in multiple clinical trials.

2. Giant cell arteritis (GCA): Giant cell arteritis is a disease in which the immune system attacks the walls of blood vessels, causing inflammation of the blood vessels and obstruction of blood flow. Tocilizumab reduces the inflammatory response of large blood vessels and reduces the incidence of complications by inhibiting the IL-6 signaling pathway. For patients with GCA, tocilizumab can effectively reduce the risk of recurrence and improve patient prognosis.

3. Systemic juvenile idiopathic arthritis (SJIA): SJIA is an autoimmune disease affecting children, manifesting as arthritis, fever and other systemic symptoms. Tocilizumab can alleviate joint inflammation and systemic symptoms by inhibiting the activity of IL-6, and improve the quality of life and disease control of pediatric patients.

4. COVID-19 (New Coronavirus Pneumonia): During the COVID-19 pandemic, tocilizumab is used to treat severe COVID-19 patients, especially those who develop severe cytokine storms. Tocilizumab reduces lung damage and improves respiratory function by inhibiting IL-6-mediated inflammatory response. Multiple studies have shown that tocilizumab can effectively reduce the cytokine storm caused by COVID-19 and reduce mortality and severe disease rates.

Reference materials:https://www.drugs.com/mtm/tocilizumab.html